(Q44551684)

4 December 2017

Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration (English)

1 reference

4 December 2017

1 reference

1 reference

Jannine G Truong

1

1 reference

4 December 2017

Kristi S Rau

series ordinal

2

1 reference

4 December 2017

Glen R Hanson

series ordinal

3

1 reference

4 December 2017

Annette E Fleckenstein

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

European Journal of Pharmacology

4 December 2017

1 reference

4 December 2017

474

1 reference

4 December 2017

2-3

1 reference

4 December 2017

223-226

1 reference

Molecular mechanisms in synaptic vesicle recycling

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

A single methamphetamine administration rapidly decreases vesicular dopamine uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Pre-clinical studies of pramipexole: clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Understanding cell death in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Dopamine transporters and neuronal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Two endocytic recycling routes selectively fill two vesicle pools in frog motor nerve terminals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

The synaptic vesicle cycle revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

alpha-synuclein and cytosolic dopamine: stabilizing a bad situation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

Oxidative stress and neurodegenerative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2902080-6

10.1016/S0014-2999(03)02080-6

7 January 2021

Identifiers

DOI

1 reference

release_rl746pibwramdcdikl4go2oj7u

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rl746pibwramdcdikl4go2oj7u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference